MEF2BD83V Mouse

Expression of the mutant MEF2BD38V allele was induced in germinal centre- derived B cells by crossing with C<U+03B3>1-Cre mice.

Contributors

Inventor Institute
Riccardo Dalla-Favera The Trustees of Columbia University in the City of New York
SKU: 154096
Product description: Diffuse large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) are the two most common forms of mature B cell lymphoid neoplams, accounting for over 50% of all diagnoses. Mutant MEF2B (MEF2BD83V) is the most common lymphoma associated oncogene. MEF2BD83V expression in mice leads to GC enlargement and lymphoma development, a phenotype that becomes fully penetrant in combination with BCL2 de-regulation, an event associated with human MEF2B mutations. Expression of the mutant MEF2BD38V allele was induced in germinal centre- derived B cells by crossing with C1-Cre mice.
Alternate name: Myocyte Enhancer Factor 2B, Serum Response Factor-Like Protein 2, RSRFR2, XMEF2
Conditional description: Conditional Knockin mice that express mutant MEF2BD38V upon recombination by Cre-recombinase
Genetic background: The conditional Mef2bstopD83V allele was generated by introducing a single nucleotide change by site directed mutagenesis leading to the D83V amino-acid change in exon 3. The neomycin-resistance marker followed by a triple-polyA, flanked by two loxP sites was introduced upstream the exon 3 carrying the D83V mutation. Correctly targeted mouse ES cells were injected into blastocysts derived from C57BL/6 mice to generate chimeras.
Production details: The conditional Mef2bstopD83V allele was generated by introducing a single nucleotide change by site directed mutagenesis leading to the D83V amino-acid change in exon 3. The neomycin-resistance marker followed by a triple-polyA, flanked by two loxP sites was introduced upstream the exon 3 carrying the D83V mutation. Correctly targeted mouse ES cells were injected into blastocysts derived from C57BL/6 mice to generate chimeras.
Cat. #: 154096
Research Fields: Cancer; Immunology
Target: MEF2B
Disease: B-Cell Lymphoma
Model: Knock-In
Zygosity: Homozygous
Strain: C57BL/6
Shipping conditions: Embryo/Spermatoza- Dry Ice
References:

Brescia et al. 2018. Cancer Cell. 34(3):453-465.e9. PMID: 30205047.

MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis.

Related Tools for Mouse models

Cat. # Tool Name
151442 Inva5b1 Mouse Key Info View Tool
151475 Raf KI D486A Mouse Key Info View Tool
151478 caMEK1 Mouse Key Info View Tool
151519 BRaf1 KI Mouse Key Info View Tool
151556 UNG Mouse Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.